@article{14d582dba9f5411896c2b9e59e5dce6e,
title = "The importance of the circadian system & sleep for bone health",
abstract = "Adequate sleep timed appropriately during the circadian night is important for numerous biological processes and systems. New evidence suggests that both sleep timing and duration may be important for optimal bone health as well. This review examines the diurnal variation of bone turnover markers (BTMs) and the importance of circadian clock genes in regulating bone mass. In addition, this review explores the evidence for a link between shift work (and its associated disturbances in sleep duration/quality and circadian alignment) and alterations in bone metabolism and bone health. Finally, we review how commonly used medications and over-the-counter substances (e.g. caffeine, melatonin) complicate the relationship between sleep and circadian disorders and bone health.",
keywords = "Bone, Bone turnover, Circadian, Fracture, Sleep",
author = "Swanson, {Christine M.} and Kohrt, {Wendy M.} and Buxton, {Orfeu M.} and Everson, {Carol A.} and Wright, {Kenneth P.} and Orwoll, {Eric S.} and Shea, {Steven A.}",
note = "Funding Information: SAS was supported by the Oregon Institute of Occupational Health Sciences ( ORS 656.630 ) at Oregon Health & Science University via funds from the Division of Consumer and Business Services of the State of Oregon. Outside of the current work, SAS receives support from NIH grants R01 HL125893 , HL125893-03S1 and R01 HL140577 (to SA Shea), NIH grant R01 HL118601 (to FA Scheer), DOD grant PT150133 (to L Hammer), and CDC grant U19 OH010154 (to WK Anger). Funding Information: Outside of the current work, ESO as PI for the The Osteoporotic Fractures in Men (MrOS) Study, is supported by National Institutes of Health funding via the following institutes: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research, under the following grant numbers: U01AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01AR066160, and UL1 TR000128. Funding Information: Outside of the current work, CMS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number K23 AR070275 . Funding Information: Outside of the current work, KPW has current support from the National Institutes of Health funding via the following institutes: National Heart, Lung and Blood Institute (NHLBI), National Institute of Child Health and Human Development (NICHD), under the following grant numbers: R01HL132150, R01 HL135598, R01 HL131458, U01 NIH HL111478, R01 HD087707; and from the Office of Naval Research MURI N00014-15-1-2809 and CurAegis Inc., PAC-12 and Philips Inc. Funding Information: OMB Previously served as consultant to Takeda Pharmaceuticals North America (speaker's bureau), Dinsmore LLC (expert witness testimony), Matsutani America (scientific advisory board), and Chevron (speaking fees). Outside of the submitted work, prior investigator-initiated research grant support from Sepracor ( NCT00555750 ; NCT00900159 ) (now Sunovion) and Cephalon ( NCT00895570 ) (now Teva). Outside of the current work, OMB received two subcontract grants to Penn State from Mobile Sleep Technologies (NSF/STTR #1622766, NIH/NIA SBIR R43AG056250). Publisher Copyright: {\textcopyright} 2018",
year = "2018",
month = jul,
doi = "10.1016/j.metabol.2017.12.002",
language = "English (US)",
volume = "84",
pages = "28--43",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
}